Topic: opioids

Nektar pain drug NKTR-181 hits endpoint in phase 3

A phase 3 trial of Nektar Therapeutics’ chronic pain asset NKTR-181 has met its primary endpoint. The clinical trial linked the mu-opioid to a statistically significant improvement in pain scores over placebo, giving Nektar efficacy data to back up an earlier study on the candidate’s abuse potential.